SciClone Pharmaceuticals Story Overview

SCLN -- USA Stock  

null 11.15  0.00  0.00%

Macroaxis does not monitor all media channels or aggregates social signals for SciClone Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on SciClone Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for SciClone Pharmaceuticals. Also please take a look at SciClone Pharmaceuticals Hype Analysis, SciClone Pharmaceuticals Correlation and SciClone Pharmaceuticals Performance.
Sale by Hong Zhao of 12500 shares of SciClone Pharmaceuticals
Filed transaction by Sciclone Pharmaceuticals officer. General open market or private sale of non-derivative or derivative security

SciClone Pharmaceuticals Inc insider trading alert for sale of common stock by Hong Zhao, CEO China Operations, on January 3, 2018. This event was filed by Sciclone Pharmaceuticals with SEC on 2017-06-14. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for SciClone Pharmaceuticals

few hours ago at www.macroaxis.com 
Purchase by Cavazza Claudio of 50000 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. General open market or private purchase of non-derivative or derivative security
3 days ago at www.macroaxis.com 
Sale by Titus Gary of 15029 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals officer. General open market or private sale of non-derivative or derivative security
few days ago at www.macroaxis.com 
Exercise or conversion by Friedhelm Blobel of 10000 shares of SciClone Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a week ago at www.macroaxis.com 
Acquisition by Woodman Dean S of 30000 shares of SciClone Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3
over two weeks ago at www.macroaxis.com 
Acquisition by Jon Saxe of 30000 shares of SciClone Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3
over two weeks ago at www.macroaxis.com 
Exercise or conversion by Schmid Hans P of 20000 shares of SciClone Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over three weeks ago at www.macroaxis.com 
Sale by Friedhelm Blobel of 10000 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. General open market or private sale of non-derivative or derivative security
over three weeks ago at www.macroaxis.com 
SciClone Pharmaceuticals exotic insider transaction detected
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals officer. Unconventional Insider trading
over three weeks ago at www.macroaxis.com 
Purchase by Cavazza Claudio of 23516 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. General open market or private purchase of non-derivative or derivative security
over a month ago at www.macroaxis.com 
Acquisition by Richard Hawkins of 15000 shares of SciClone Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3
over a month ago at www.macroaxis.com 
Sale by Friedhelm Blobel of 10000 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. General open market or private sale of non-derivative or derivative security
over three months ago at www.macroaxis.com 
Exercise or conversion by Friedhelm Blobel of 840 shares of SciClone Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over six months ago at http://bangaloreweekly.com 
Radius Health Inc Anticipated to Announce Quarterly Sales of 13.71 Million
news
BangaloreWeeklyFull coverage

Shares Owned by Institutions

Shares Owned by Institutions Comparative Analysis

  Shares Owned by Institutions 
      SciClone Pharmaceuticals Comparables 
SciClone Pharmaceuticals is rated fourth in shares owned by institutions category among related companies. Shares Owned by Institutions show percentage of the outstanding shares of stock issued by a company that are currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Peers

SciClone Pharmaceuticals Related Equities

REGN  3.36 %   
0%
63.0%
VRTX  3.22 %   
0%
61.0%
RDY  1.69 %   
0%
31.0%
SEED  1.59 %   
0%
30.0%
SCLN  0.00 %   
0%
0%
PRXL  0.05 %   
1.0%
0%
PRGO  1.16 %   
21.0%
0%
ZTS  4.75 %   
90.0%
0%
SVA  5.27 %   
100.0%
0%
Also please take a look at SciClone Pharmaceuticals Hype Analysis, SciClone Pharmaceuticals Correlation and SciClone Pharmaceuticals Performance. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
Search macroaxis.com